Unregistered User If this is not your name, click here.
		Contact Us | Order Now | Journals | Bookstore | Register a colleague
	Select a ChannelAcneAIDS and HIVAllergy OtherAlzheimer'sAnaesthesiology OtherAngina Pectoris/MIAnxietyArthritis OtherAsthmaBack PainBacterial InfectionsBladder CancerBone Marrow TransplantationBreast CancerCardiology OtherCataractCell TransplantationCervical CancerCholesterol/Lipid disordersCirrhosisClinical PharmacologyColorectal CancerCongestive Heart FailureContact DermatitisContraceptionCOPDCystic FibrosisDental and Oral DisordersDepressionDermatology OtherDiabetesDialysisEating DisordersElbowEmergency MedicineEndocrinology OtherEpilepsyErectile DysfunctionFibromyalgiaGastro OtherGeneticsGenitourinary OtherGeriatricsGERD/GastritisGlaucomaH. Pylori/UlcerHaematology OtherHair LossHeadachesHepa/Biliary OtherHepatitisHipHRTHypertensionIBDImmunologyInfectious OtherInfertilityIntensive CareIrritable Bowel SyndromeKneeLeukemiasLiver CancerLung CancerLupusLymphomasMelanomaMenopauseMultiple Sclerosis Nephrology OtherNeurologic OtherNutritional / Metabolic OtherOb/Gyn OtherObesityOncology OtherOphth. OtherOphthalmic SurgeryOrgan TransplantationOrthopaedics OtherOsteoarthritisOsteoporosisOtitisOtorhino. OtherOvarian CancerPaediatricsPainPancreatic CancerParkinson'sPregnancyProstate CancerPsychiatry OtherPulmonary OtherRadiologyRenal CancerRenal FailureRespiratory InfectionsRheumatoid arthritisRheumatology OtherRhinitisSchizophreniaShoulderSleep ApnoeaSleep DisordersSpineStrokeSTDsSurgeryThyroid DisordersTransfusionTransplant Surgery OtherTraumaUrinary IncontinenceUrinary tract infectionsVaccinologyVascular DisordersViral Infections

SEARCH   News Bookstore Medline The Web Meetings & Congresses Complete Doctor's Guide    EXPLORE :    All News   All Webcasts   All Cases   All Meetings & Congresses   All Medical Resources New drugs / indications English Dictionary Medical Dictionary Thesaurus Warning | Privacy | Awards  Favourite Journals  Click here to choose your favourite journals  Favourite Sites  Click here to choose your favourite sites  Languages  Select languageEnglishFrançais

Trisenox (Arsenic Trioxide) Enhances Effects of Glivec (STI-571) Against Chronic Myeloid Leukemia SEATTLE, WA -- May 3, 2001 -- Researchers report that Trisenox ™ (arsenic trioxide) may make Glivec® (STI-571) more effective in treating chronic myeloid leukemia (CML). Cell Therapeutics, Inc. currently markets Trisenox injection for the treatment of relapsed acute promyelocytic leukemia (APL), another form of severe leukemia. In the journal Leukemia, scientists found that combination treatment with arsenic trioxide and STI-571 is more effective at inducing cell death than either agent alone and may also have the potential to delay resistance to STI-571. The authors demonstrated that arsenic trioxide selectively decreases levels of bcr-abl, the fusion gene responsible for CML, and induces cell death in bcr-abl positive leukemia cells through a mechanism that is different and independent of abl-kinase inhibition by STI-571. As a result of these and other data, more investigators are becoming interested in studying Trisenox to treat CML. "Based on early data from China showing a high response rate to arsenic trioxide in CML patients, we have initiated studies of Trisenox in our lab," stated Brian Druker, M.D., Professor of Medicine, Oregon Health Sciences University. "What we have seen is that Trisenox is very effective at killing CML cells, and we are in the process of testing Trisenox in combination with STI-571." "This is very exciting preclinical data supporting the investigation of Trisenox in clinical trials for treating patients with CML," noted James A. Bianco, M.D., President and CEO of Cell Therapeutics, Inc. "Given that the prevalence of this type of leukemia is high, it could represent a commercially attractive application for Trisenox." Trisenox, a pharmaceutical grade arsenic product, has been approved by the Food and Drug Administration (FDA) to treat patients with relapsed or refractory APL. In general, the toxicities associated with arsenic trioxide therapy are well identified and manageable, when monitored and treated appropriately. CML is one of the two main types of chronic leukemia. Worldwide, the disease occurs in one to two cases per 100,000 people per year and is responsible for up to 20 percent of all adult leukemias. SOURCE: Cell Therapeutics, Inc. E-mail this page to a friend or colleague! To print, use this version